To include your compound in the COVID-19 Resource Center, submit it here.

CardioVascular BioTherapeutics, ProDerm L.P. deal

CardioVascular will receive $1-$10 million from ProDerm to fund future

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE